Marker Therapeutics is trading at $1.25 (-5.64%) amid broader market weakness and a 4.24% biotechnology-sector decline.
- The decline is occurring during the September 1, 2026 session.
- No fresh company-specific announcement, earnings release, regulatory action, or downgrade was identified.
- The latest identifiable company-related item was a positive H.C. Wainwright Buy reiteration on August 21, 2026; elevated rates, geopolitical tensions, and global bond-market volatility are pressuring high-beta biotech shares.